Marty joined Spring Bank in 2015 as President, Chief Executive Officer and Director. Previously, he served as CEO of Asmacure Ltée, a venture-backed, clinical-stage biopharmaceutical company which he joined in late 2010. Asmacure Ltée was acquired by a privately-held Canadian life sciences company in July 2015. Prior to Asmacure, Marty was the CEO and a director of Javelin Pharmaceuticals, Inc., a publicly-traded developer of acute care pain products, from March 2008 until July 2010, when he engineered the merger of Javelin with Hospira, Inc. He also served in various senior management roles at Schering-Plough Corporation, ViroPharma, Inc. and Reliant Pharmaceuticals, Inc. In 2007, Marty co-founded Pear Tree Pharmaceuticals, Inc., a privately-held developer of women’s healthcare products. He has been involved with or led the commercialization of several important therapies, the direct negotiation of numerous licensing and M&A transactions, multiple private and public capital fundraising efforts and the successful submission of major product regulatory filings. Marty also served as a director on the boards of four private and public biopharmaceutical development companies and currently serves on the board of Asmacure Ltée. Marty holds a BSc in communications from the University of Texas at Austin. He is a trustee of the Barn for the Poorest of the Poor, a non-profit food pantry based in New Jersey.
Kris is an innovator in the fields of nucleic acid chemistry, bioorganic chemistry and pharmaceutical sciences. He was co-founder and VP of Discovery of Origenix Technologies, Inc. from 1998 to 2002. There he directed a team of 30 scientists in chemistry and biology and was instrumental in advancing several programs from discovery to clinical development. From 1993 to 1998, Kris was a Senior Scientist and Associate Director of the Discovery Group at Hybridon, Inc. (now Idera Pharmaceuticals, Inc.). Previously, Kris was a Professor of Medicinal Chemistry at the University of Bombay, a Visiting Scientist at the University of Texas, M.D. Anderson Cancer Center and a Visiting Scientist at the Center for Biologics Evaluation and Research at FDA/NIH. Kris received his BS (Hons) in chemistry, BS and MS degrees in Medicinal and Pharmaceutical Chemistry from the University of Bombay. He received his PhD degree in Pharmaceutical Sciences from the University of the Pacific, Stockton, California and carried out postdoctoral work at the OakRidge National Laboratory and at the Johns Hopkins University. He is an author of over 100 scientific papers and several books on organic synthesis and is an inventor of more than 100 patents and patent applications. In 2004, Kris was elected as a Fellow of Royal Society of Chemistry, UK and in 2008 he was elected as a Fellow of International Society of Physical Sciences. In 2004, he was awarded the M. L. Khorana Memorial Award by the Indian Pharmaceutical Association and in 2003 elected as the UICT Diamond Jubilee Distinguished Fellow in Pharmaceutical Sciences. Kris has served on the Scientific Advisory Board of Topigen Pharmaceuticals, Inc. and currently serves on the National Institutes of Health (NIH) review panel for grants and contracts.
Don has been Spring Bank’s Vice President of Operations & Corporate Development since March 2011 and served as a consultant to the Company from 2008 to March 2011. Prior to joining Spring Bank, he was Executive Director of Corporate Development at Idenix Pharmaceuticals, Inc. from 2005 until 2008. Prior to Idenix, Mr. Mitchell held a series of senior marketing positions at Amgen, Inc. Prior to Amgen, Mr. Mitchell was principal consultant at PricewaterhouseCoopers. Mr. Mitchell started his career at Novartis Pharmaceuticals, where he held a series of sales, marketing and business development positions of increasing responsibility. He has a BS from the United States Naval Academy and an MBA from the Darden Graduate School of Business Administration at the University of Virginia. Prior to obtaining his MBA, Mr. Mitchell served as a communications officer and an assistant engineer of the Nuclear Submarines division of the United States Navy.
Kevin brings to Spring Bank over 13 years of experience in the biopharmaceutical industry. Prior to joining Spring Bank, he was senior director, nonclinical and translational research, at Retrophin, Inc., in Cambridge, MA. Before Retrophin, Kevin served in various scientific and research roles of increasing responsibility at Shire Pharmaceuticals and Merck. He has authored more than twelve peer-reviewed publications and contributed to several issued patents and patent applications. Kevin received his B.A. in biology from the University of Richmond, his Ph.D. in biochemistry and molecular biophysics from Virginia Commonwealth University School of Medicine and was a postdoctoral fellow at Massachusetts Institute of Technology.
Dr. Abbas is a pharmaceutical physician with nearly 20 years of clinical development, medical affairs and pharmacovigilance experience in oncology and immunology therapeutic areas. Prior to joining Spring Bank, he was associate vice president of clinical development in oncology at the biopharmaceutical company, Kadmon Inc. Prior to his work with Kadmon, he was a consultant physician at Ziopharm Oncology and Celgene Corp. where he provided scientific and medical expertise regarding drug development and clinical trials. Prior to this, he held roles of increasing responsibility in oncology clinical development and clinical safety at Merck KGaA, Astellas Pharma and Exelixis Inc. He has also held consultant physician roles with Bristol-Myers Squibb, Boehringer Ingelheim and Pfizer. In addition to his pharmaceutical experience, he was a senior house surgeon at the Mayo Hospital and Children’s Hospital in Lahore, Pakistan. Dr. Abbas received his M.B., B.S./M.D. from King Edward Medical University, Lahore.
Garrett Winslow has been Spring Bank’s Vice President, Legal since January 2017. Prior to joining Spring Bank, he was a member in the Corporate and Securities group at Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. in Boston, Massachusetts, where he advised public and private companies on securities law compliance, corporate governance matters, and mergers and acquisitions. Mr. Winslow received his Masters in Taxation from Boston University Law School, J.D. degree from Suffolk University Law School and B.A. degree in Business Administration from the University of Washington.